Additionally, gefitinib triggers autophagy-mediated degradation of EGFR in lung cancer cells resistant to TKIs as a protective mechanism, thereby promoting the development of resistance driven by T790M mutation [31]. This evidence concerns the gene EGFR and lung carcinoma.